Abstract: A method of using blue light for inducing angiogenesis for treatment of wounds, burns, and other injuries, or to treat ischemic conditions, is provided. The method comprises irradiating a target with a visible light, wherein the visible light has a dominant emission wavelength ranging from 435 nm to 520 nm, and effective fluence of the visible light ranges from about 0.15 J/cm2 to about 17 J/cm2.

Abstract: The invention relates to a process for obtaining a skin substitute, comprising the following steps: a) mixing fibroblasts, endothelial cells and hydrogel of exclusively biological origin; b) incubating the mixture obtained in step a) for a sufficient time and under suitable conditions to obtain a pre-vascularized dermis; c) adding keratinocytes to the pre-vascularized dermis of step b) to obtain a skin substitute; wherein said fibroblasts, endothelial cells and keratinocytes were obtained from pluripotent stem cells.

Abstract: The invention is directed to a light source device comprising a light emitting element for emitting a blue light having a wavelength ranging from 435 to 500 nm, the light source device being configured to provide the blue light to at least one cell at a transmitted fluence ranging from 0.01 to 18. J/cm2 to promote or induce growth and proliferation of the cell and wherein the light emitting element has a power density ranging from 0.05 to 30 mW/cm2. The invention is also directed to a light source assembly comprising a product adapted to be in contact with the skin or a wound and a light source device connected to the product for providing blue light to at least one skin cell, preferably of the wound.

Abstract: A light source device including a light emitting element for emitting a light having the following characteristics: a wavelength ranging from 435 to 520 nm, and a power density greater than 20 mW/cm2, the light source device provides an effective fluence to any contaminating and/or pathogenic agent greater than 11 J/cm2. Also, a light source assembly including a product adapted to be in contact with a support or a medium, preferably the skin or a wound and a light source device connected to the product for providing light to at least one contaminating and/or pathogenic agent present on a support or in a medium.

Abstract: The invention is directed to a light source device (10) comprising a light emitting element (12) for emitting a blue light having a wavelength ranging from 435 to 500 nm, the light source device (10) being configured to provide the blue light to at least one cell (C) at a transmitted fluence ranging from 0.01 to 18. J/cm2 to promote or induce growth and proliferation of the cell (C) and wherein the light emitting element (12) has a power density ranging from 0.05 to 30 mW/cm2. The invention is also directed to a light source assembly comprising a product adapted to be in contact with the skin or a wound and a light source device (10) connected to the product for providing blue light to at least one skin cell (C), preferably of the wound.

Abstract: The subject matter of the present invention is a synthetic polysulfated oligosaccharide having 1 to 4 monosaccharaide units, salts thereof, or complexes thereof, at a concentration greater than or equal to 70 mg/mL, for use thereof for activating angiogenesis, in particular for activating angiogenesis during wound healing.

Abstract: The present invention relates to a compound selected among the synthetic polysulphated oligosaccharides having 1 to 4 ose units and the salts and complexes thereof to be used for the treatment of wounds resulting in pathological scars selected among hypertrophic, retractile or atrophic scars. Said use is preferred in particular in patients that have a predisposition to developing hypertrophic, retractile or atrophic scars. According to a second aspect, the invention also relates to said compound for the use thereof in order to inhibit the differentiation of fibroblasts into myofibroblasts during the cicatrisation of wounds resulting in pathological scars selected among hypertrophic, retractile or atrophic scars.

Abstract: The present invention relates to a topical composition, in particular a cosmetic and/or dermatological composition, to be used for preventing and/or treating stretch marks, including, in a physiologically acceptable medium, an effective amount of at least one synthetic polysulfated oligosaccharide having 1 to 4 glycose units, the salts thereof, and/or the derivatives thereof. The invention also relates to a cosmetic method, in particular for treating stretch marks, including at least one step of applying said composition to the skin.

Abstract: The present invention relates to a method and kit for the classification and prognosis of wounds of mammalian, in particular in human. The method defines a molecular signature that enables one to characterize a pathological wound healing such as chronic or non-healing wound.

Abstract: The invention relates to methods of diagnosis or prognosis of a tissue or organ fibrosis (e.g., skin fibrosis, hypertrophic scar or a keloid) in a reparative or reactive process comprising the step of determining the levels of expression of genes encoding different molecular markers in a sample of a tissue or organ from a mammalian, wherein different genes markers are studied.

Abstract: The present invention relates to a topical composition, in particular a cosmetic and/or dermatological composition, to be used for preventing and/or treating stretch marks, including, in a physiologically acceptable medium, an effective amount of at least one synthetic polysulfated oligosaccharide having 1 to 4 glycose units, the salts thereof, and/or the derivatives thereof. The invention also relates to a cosmetic method, in particular for treating stretch marks, including at least one step of applying said composition to the skin.

Abstract: The present invention relates to a compound selected among the synthetic polysulphated oligosaccharides having 1 to 4 ose units and the salts and complexes thereof to be used for the treatment of wounds resulting in pathological scars selected among hypertrophic, retractile or atrophic scars. Said use is preferred in particular in patients that have a predisposition to developing hypertrophic, retractile or atrophic scars. According to a second aspect, the invention also relates to said compound for the use thereof in order to inhibit the differentiation of fibroblasts into myofibroblasts during the cicatrisation of wounds resulting in pathological scars selected among hypertrophic, retractile or atrophic scars.